AbbVie Acquires Aliada, Strengthens Alzheimer's Pipeline

AbbVie has officially finalised its acquisition of Aliada Therapeutics, merging the company into its operations. Aliada's key experimental drug, ALIA-1758, is a leading anti-pyroglutamate amyloid beta (3pE-Aβ) antibody designed to treat Alzheimer's disease. This treatment is currently undergoing a Phase 1 clinical trial. ALIA-1758 uses its innovative blood-brain barrier (BBB) — crossing technology, significantly improving targeted therapies' delivery to the central nervous system (CNS).

Dawn Carlson, M.D., M.P.H., vice president of neuroscience development at AbbVie, said in a statement, "Alzheimer's disease poses a significant public health challenge, impacting millions worldwide and is becoming more prevalent as populations age. With the acquisition complete, we look forward to advancing potentially disease-modifying therapies such as ALIA-1758 for Alzheimer's disease and bolstering our neuroscience discovery and development efforts by leveraging Aliada's novel CNS drug delivery platform."